2Porebska I,Harlozinska A,Bojarowski T.Expression of the tyrosine kinase activity growth factor receptors(EGFR,ERB B2,ERB B3) in colorectal adenocarcinomas and adenomas[J].Tumour Biol,2000,21:105.
3Goldstein N S,Armin M.Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma:implications for a standardized scoring system[J].Cancer 2001,92:1331.
4Foon K A,Yang X D,Weiner L M,et al.Preclinical and clinical evaluations of ABX-EGF,a fully human anti-epidermal growth factor receptor antibody[J].Int J Radiat Oncol Biol Phys,2004,58:984.
5Saltz L.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J].J Clin Oncol,2004,22(6):1.
7Jose B. Why the epidermal growth factor receptor? The rational for cancer therapy. Oncologist,2002, (7 Suppl 4) :2-8.
8Caponigro F,Basile M,de Rosa V,et al. New drugs in cancer therapy,National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs,2005,16(2) :211-221.
9Safavy A, Bonner JA, Waksal HW, et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.Bioconjug Chem,2003,14(2) :302-310.
10Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res,2004,10( 12 Pt 2) :4241S-4244S.
3Kabbinavar F,Hurwitz HI,Fehrenbacher L,et al.Phase Ⅱ,randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV)with FU/ LV alone in patients with metastatic colorectal cancer[J].J Clin Oncol,2003,21 (1):60-65.
4Wood JM,Bold G,Buchdunger E,et al.PTK787/ ZK 222584,a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases,impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration[J].Cancer Res,2000,60 (8):2178-2189.
5Bold G,Altmann KH,Frei J,et al.New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis[J].J Med Chem,2000,43 (12):2310-2323.
6Javaid MH,Smith GC,Martin NM,et al.4-Heteroarylmethyl substituted phthalazinone derivatives as PARP-1 inhibitors,their preparation,pharmaceutical compositions,and use in therapy:WO,2006021801[P].2006-03-02.
7Bold G,Frei J,Traxler P,et al.Preparation of 1-arylamino-4-pyridylmethylphthalazines and analogs as VEGF receptor inhibitors:WO,9835958[P].1998-08-20.
